Skip to main content
CIZZLE BIOTECHNOLOGY HOLDINGS PLC logo

CIZZLE BIOTECHNOLOGY HOLDINGS PLC — Investor Relations & Filings

Ticker · CIZ ISIN · GB00BNG2VN02 LEI · 213800G3OS3SA2J1Y358 IL Professional, scientific and technical activities
Open in API
Filings indexed 305 across all filing types
Latest filing 2026-04-30 Annual Report
Country GB United Kingdom
Listing IL CIZ

About CIZZLE BIOTECHNOLOGY HOLDINGS PLC

https://cizzlebiotechnology.com/

Cizzle Biotechnology Holdings PLC is a cancer diagnostics developer focused on the early detection of lung cancer. The company is advancing a non-invasive, cost-effective blood test designed to identify lung cancer at its earliest stages, often before symptoms appear. The test utilizes a proprietary CIZ1B biomarker and an advanced immunoassay. Its primary goal is to improve patient outcomes by enabling swift, curative medical intervention. The technology aims to streamline the diagnostic pathway, reduce reliance on CT scans which can have high false-positive rates, and eliminate unnecessary invasive follow-up procedures. The company, a spin-out from the University of York, is conducting clinical trials to support global regulatory approval and adoption of its technology.

Recent filings

Filing Released Lang Actions
Final results for the year ended 31 December 2025
Annual Report FY 2025
2026-04-30 English
£250,000 Funding Facility
Capital/Financing Update Classification · 1% confidence The document is an RNS announcement by Cizzle Biotechnology Holdings PLC detailing its entry into a new £250,000 funding facility through the issue of convertible loan notes and warrants. It focuses on financing terms, drawdown schedule, and investor commitments, which aligns with updates on company fundraising and capital structure changes. Therefore, it is classified as a Capital/Financing Update (CAP).
2026-04-02 English
Progress on Launch of Biomarker Test in USA
Regulatory Filings Classification · 1% confidence The document is an official announcement from Cizzle Biotechnology Holdings PLC regarding progress on the commercial launch of a biomarker test and updates to royalty payment schedules. It is distributed via the London Stock Exchange's RNS (Regulatory News Service) and contains inside information as per UK MAR. While it discusses financial arrangements, it is a corporate news announcement rather than a formal financial report, audit, or proxy statement. It fits the definition of a Regulatory Filing (RNS) as it is a general regulatory announcement regarding company operations and licensing agreements.
2026-02-23 English
Patent Granted in Canada
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement issued via the London Stock Exchange's RNS (Regulatory News Service). It details a specific corporate development—the granting of a patent in Canada for the company's CIZ1B lung cancer biomarker test. As this is a general corporate announcement regarding business operations and intellectual property that does not fit into specific categories like financial reports, dividends, or management changes, it falls under the 'Regulatory Filings' (RNS) category.
2026-02-04 English
£250,000 Convertible Loan Note Issue
Capital/Financing Update Classification · 1% confidence The document is an announcement from Cizzle Biotechnology Holdings PLC regarding the issuance of convertible loan notes to raise £250,000. It details the terms of the financing, the use of proceeds, and the issuance of warrants. This falls under the category of company fundraising and financing activities. While it is distributed via RNS, the content is specifically a capital/financing update rather than a general regulatory filing or report publication announcement.
2025-11-05 English
LOI with leading UK Clinical Diagnostic Group
Regulatory Filings Classification · 1% confidence The document is an official announcement from Cizzle Biotechnology Holdings PLC regarding the signing of a Letter of Intent (LOI) for a partnership with a UK clinical diagnostic group. It is distributed via the Regulatory News Service (RNS) of the London Stock Exchange. Since it is a corporate announcement regarding business operations and partnerships that does not fit into specific categories like M&A (which usually implies a takeover or merger) or financial reporting, it is classified as a general regulatory filing.
2025-11-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.